Renal involvement in fatal cases of chikungunya virus infection
Chikungunya virus (CHIKV) was first isolated in Tanzania (then Tanganyika) in 1953, when it was identified as the agent responsible for an outbreak of febrile disease on a Makonde Plateau [1]. To date, CHIKV infection has been documented in Africa, several islands in the Indian Ocean, Asia and recently in the Americas, including United States. In addition, there have been outbreaks and imported cases in several European countries [2,3]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 26, 2018 Category: Virology Authors: Marcela Mercado, Jorge Acosta-Reyes, Edgar Parra, Luis Guzm án, Mauricio Beltrán, Philippe Gasque, Carlos Mejía-García, Diego Viasus Tags: Short communication Source Type: research
Trends in testing algorithms used to diagnose HIV infection, 2011-2015, United States and 6 dependent areas
The Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention Strategic Plan 2017-2020 has four main goals for prevention of human immunodeficiency virus (HIV) infection: 1) prevent new HIV infections, 2) improve health outcomes for persons living with HIV, 3) reduce HIV-related disparities and health inequities, and 4) continually improve effectiveness and efficiency of operations [1]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 26, 2018 Category: Virology Authors: Anne Harwood Peruski, Xueyuan Dong, Richard M. Selik Source Type: research
Renal involvement in fatal cases of chikungunya virus infection
Chikungunya virus (CHIKV) was first isolated in Tanzania (then Tanganyika) in 1953, when it was identified as the agent responsible for an outbreak of febrile disease on a Makonde Plateau [1]. To date, CHIKV infection has been documented in Africa, several islands in the Indian Ocean, Asia and recently in the Americas, including United States. In addition, there have been outbreaks and imported cases in several European countries [2,3]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 26, 2018 Category: Virology Authors: Marcela Mercado, Jorge Acosta-Reyes, Edgar Parra, Luis Guzman, Mauricio Beltr án, Philippe Gasque, Carlos Mejía-García, Diego Viasus Tags: Short communication Source Type: research
The current landscape of nucleic acid tests for filovirus detection
The Ebolaviruses are a group of closely related viruses in the filoviridae family. Filoviruses have negative-sense RNA genomes protected by the nucleocapsid protein (Fig. 1A). There are five distinct Ebolavirus species; Bundibugyo (BDBV), Reston (RESTV), Sudan (SUDV), Ta ï forest (TAFV, formerly Cote d’Ivoire Ebolavirus) and Zaire (EBOV). All five members can cause infections in humans albeit with a wide spectrum of disease severity. The Zaire and Sudan species cause Ebolavirus Disease (EVD) with a fatality rate ranging from 40 to 90% [1]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: David J. Clark, John Tyson, Andrew D. Sails, Sanjeev Krishna, Henry M. Staines Source Type: research
Viral load and antibody boosting following herpes zoster diagnosis
Primary infection with varicella zoster virus (VZV) causes chickenpox, following which the virus establishes latency. It reactivates in up to 25% of individuals to cause the painful dermatomal rash known as shingles (herpes zoster). During chickenpox or shingles, viral DNA is detectable in skin lesions, blood and saliva [1,2]. Viral replication is accompanied by boosting of VZV antibodies consistent with antigenic, or endogenous, boosting. Few data exist, however, confirming the relationship between viral load and antibody titres during, and following, acute clinical VZV disease. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: Charlotte Warren-Gash, Harriet Forbes, Peter Maple, Mark Quinlivan, Judith Breuer Tags: Short communication Source Type: research
Performance evaluation of four type-specific commercial assays for detection of herpes simplex virus type 1 antibodies in a Middle East and North Africa population
Herpes simplex virus type 1 (HSV-1) is one of the most prevalent (mostly asymptomatic) infections worldwide [1,2]. Infections with HSV-1 are associated with oral, ocular, cutaneous, and central nervous system manifestations, and can result in mild to severe morbidities such as gingivostomatitis, neonatal herpes, corneal blindness, meningitis, and encephalitis [3,4]. Although HSV-1 infection is commonly associated with orolabial herpes, evidence indicates a growing role for HSV-1 as a sexually transmitted infection (STI) and as a cause of genital herpes, even surpassing the role of HSV-2 for incident genital herpes in some ...
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: Rana S. Aldisi, Malaz S. Elsidiq, Soha R. Dargham, Afifah S. Sahara, Enas S. Al-Absi, Mariam Y. Nofal, Layla I. Mohammed, Laith J. Abu-Raddad, Gheyath K. Nasrallah Source Type: research
The current landscape of nucleic acid tests for filovirus detection
The Ebolaviruses are a group of closely related viruses in the filoviridae family. Filoviruses have negative-sense RNA genomes protected by the nucleocapsid protein (Fig. 1A). There are five distinct Ebolavirus species; Bundibugyo (BDBV), Reston (RESTV), Sudan (SUDV), Ta ï forest (TAFV, formerly Cote d’Ivoire Ebolavirus) and Zaire (EBOV). All five members can cause infections in humans albeit with a wide spectrum of disease severity. The Zaire and Sudan species cause Ebolavirus Disease (EVD) with a fatality rate ranging from 40-90% [1]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: David J. Clark, John Tyson, Andrew Sails, Sanjeev Krishna, Henry M. Staines Source Type: research
Performance Evaluation of Four Type-specific Commercial Assays for Detection of Herpes Simplex Virus Type 1 Antibodies in a Middle East and North Africa Population
Herpes simplex virus type 1 (HSV-1) is one of the most prevalent (mostly asymptomatic) infections worldwide [1,2]. Infections with HSV-1 are associated with oral, ocular, cutaneous, and central nervous system manifestations, and can result in mild to severe morbidities such as gingivostomatitis, neonatal herpes, corneal blindness, meningitis, and encephalitis [3,4]. Although HSV-1 infection is commonly associated with orolabial herpes, evidence indicates a growing role for HSV-1 as a sexually transmitted infection (STI) and as a cause of genital herpes, even surpassing the role of HSV-2 for incident genital herpes in some ...
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: Rana S. Aldisi, Malaz S. Elsidiq, Soha R. Dargham, Afifah S. Sahara, Enas S Al-Absi, Mariam Y. Nofal, Layla I. Mohammed, Laith J. Abu-Raddad, Gheyath K. Nasrallah Source Type: research
Viral load and antibody boosting following herpes zoster diagnosis
Primary infection with varicella zoster virus (VZV) causes chickenpox, following which the virus establishes latency. It reactivates in up to 25% of individuals to cause the painful dermatomal rash known as shingles (herpes zoster). During chickenpox or shingles, viral DNA is detectable in skin lesions, blood and saliva [1,2]. Viral replication is accompanied by boosting of VZV antibodies consistent with antigenic, or endogenous, boosting. Few data exist, however, confirming the relationship between viral load and antibody titres during, and following, acute clinical VZV disease. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 22, 2018 Category: Virology Authors: Charlotte Warren-Gash, Harriet Forbes, Peter Maple, Mark Quinlivan, Judith Breuer Tags: Short communication Source Type: research
Varicella Zoster Immunoglobulin G (VZIG) —Do current guidelines advocate overuse?
We recently coordinated a large Varicella-Zoster Virus (VZV) contact screening exercise following a series of exposures to immunosuppressed patients in a renal transplant clinic. The index case was an immunosuppressed renal transplant patient and was seen in 3 renal transplant outpatient clinics with VZV vesicles on her face and exposed parts of the body. As she spent time in the waiting room of the clinics, comprised of an entirely immunosuppressed population, a large contact tracing and screening exercise was initiated. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 20, 2018 Category: Virology Authors: David Harrington, Tanzina Haque Tags: Letter to the editor Source Type: research
Varicella Zoster Immunoglobulin G (VZIG) — Do current guidelines advocate overuse?
We recently coordinated a large Varicella-Zoster Virus (VZV) contact screening exercise following a series of exposures to immunosuppressed patients in a renal transplant clinic. The index case was an immunosuppressed renal transplant patient and was seen in 3 renal transplant outpatient clinics with VZV vesicles on her face and exposed parts of the body. As she spent time in the waiting room of the clinics, comprised of an entirely immunosuppressed population, a large contact tracing and screening exercise was initiated. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 20, 2018 Category: Virology Authors: David Harrington, Tanzina Haque Tags: Letter to the editor Source Type: research
Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium
Hepatitis E virus (HEV) is a small, non-enveloped, single stranded RNA virus. Four HEV genotypes exist. HEV genotypes 1 and 2 are typically associated with human epidemic outbreaks in developing countries. They are transmitted between humans by the fecal-oral route. By contrast, HEV genotypes 3 and 4 are transmitted foodborne and zoonotically from animal reservoirs. They usually occur as sporadic cases and are emerging pathogens in the developed world [1 –6]. HEV can be complicated by serious complications such as neurologic disorders. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 19, 2018 Category: Virology Authors: Lien Cattoir, Frederik Van Hoecke, Tom Van Maerken, Eveline Nys, Inge Ryckaert, Matthias De Boulle, Anja Geerts, Xavier Verhelst, Isabelle Colle, Veronik Hutse, Vanessa Suin, Magali Wautier, Steven Van Gucht, Hans Van Vlierberghe, Elizaveta Padalko Source Type: research
Clinical burden of Hepatitis E virus infection in a tertiary care center in Flanders, Belgium
Hepatitis E virus (HEV) is a small, non-enveloped, single stranded RNA virus. Four HEV genotypes exist. HEV genotypes 1 and 2 are typically associated with human epidemic outbreaks in developing countries. They are transmitted between humans by the fecal-oral route. By contrast, HEV genotypes 3 and 4 are transmitted foodborne and zoonotically from animal reservoirs. They usually occur as sporadic cases and are emerging pathogens in the developed world [1 –6]. HEV can be complicated by serious complications such as neurologic disorders. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - March 19, 2018 Category: Virology Authors: Lien Cattoir, Frederik Van Hoecke, Tom Van Maerken, Eveline Nys, Inge Ryckaert, Matthias De Boulle, Anja Geerts, Xavier Verhelst, Isabelle Colle, Veronik Hutse, Vanessa Suin, Magali Wautier, Steven Van Gucht, Hans Van Vlierberghe, Elizaveta Padalko Source Type: research
Neonates with congenital Cytomegalovirus and hearing loss identified via the universal newborn hearing screening program
Congenital CMV is the most common non-genetic cause of fetal malformation in the developed world [1 –3]. It is estimated that each year ∼380 neonates in Australia and ∼3600 neonates in the USA, develop disease due to congenital CMV infection. The complications of congenital CMV infection usually extend into adulthood, causing lifelong disabilities, including sensorineural hearing loss (SNHL) and neurodevelopmental disability [4–6]. Approximately 10% of congenital CMV-infected neonates are born with SNHL, whereas many (∼15%) initially asymptomatic CMV-infected neonates develop hearing loss postnatally before the a...
Source: Journal of Clinical Virology - March 15, 2018 Category: Virology Authors: William D. Rawlinson, Pamela Palasanthiran, Beverly Hall, Laila Al Yazidi, Michael J. Cannon, Carolyn Cottier, Wendy J. van Zuylen, Monica Wilkinson Source Type: research
Neonates with congenital cytomegalovirus and hearing loss identified via the universal newborn hearing screening program
Congenital CMV is the most common non-genetic cause of fetal malformation in the developed world [1 –3]. It is estimated that each year ∼380 neonates in Australia and ∼3,600 neonates in the USA, develop disease due to congenital CMV infection. The complications of congenital CMV infection usually extend into adulthood, causing lifelong disabilities, including sensorineural hearing loss (SNHL ) and neurodevelopmental disability [4–6]. Approximately 10% of congenital CMV-infected neonates are born with SNHL, whereas many (∼15%) initially asymptomatic CMV-infected neonates develop hearing loss postnatally before the...
Source: Journal of Clinical Virology - March 15, 2018 Category: Virology Authors: William D. Rawlinson, Pamela Palasanthiran, Beverly Hall, Laila Al Yazidi, Michael J. Cannon, Carolyn Cottier, Wendy J. van Zuylen, Monica Wilkinson Source Type: research
